Zobrazeno 81 - 90
of 523
pro vyhledávání: '"Vered Stearns"'
Autor:
Linda M. Delahanty, Thomas A. Wadden, Pamela J. Goodwin, Catherine M. Alfano, Cynthia A. Thomson, Melinda L. Irwin, Marian L. Neuhouser, Tracy E. Crane, Elizabeth Frank, Patricia A. Spears, Bonnie P. Gillis, Dawn L. Hershman, Electra D. Paskett, Judith Hopkins, Vanessa Bernstein, Vered Stearns, Julia White, Clifford Hudis, Eric P. Winer, Lisa A. Carey, Ann H. Partridge, Jennifer A. Ligibel
Publikováno v:
Obesity (Silver Spring)
The Breast Cancer Weight Loss (BWEL) trial, is a randomized, controlled trial designed to determine whether weight loss after breast cancer diagnosis can reduce the risk of cancer recurrence in women with overweight or obesity. BWEL will compare the
Autor:
Nelli Zafman, Carol D. Riley, Jessica M. Ruck, Katherine Clegg Smith, Karen L. Smith, Jennifer Y. Sheng, Vered Stearns, Claire F. Snyder, Sarah Skuli, Antonio C. Wolff, Elissa Thorner
Publikováno v:
Support Care Cancer
Purpose: To better understand the impact of cancer and treatment on outcomes and guide program development, we evaluated breast cancer survivors at risk for long-term medical and psychosocial issues who participated in survivorship care visits (SVs)
Publikováno v:
Med (N Y)
Tumor evolution drives tumor progression, therapeutic resistance, and metastasis. Therefore, new predictive medicine strategies that adapt with a tumor are needed to improve patient outcomes. The techniques used in weather prediction are mathematical
Autor:
Julie A. Douglas, Daniel L. Hertz, N. Lynn Henry, Zeruesenay Desta, Daniel F. Hayes, Todd C. Skaar, James M. Rae, Christina L. Gersch, Vered Stearns, Ana Maria Storniolo, Kelley M. Kidwell
Publikováno v:
Pharmacogenet Genomics
OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may b
Autor:
Hyo S. Han, Bridget Riley-Gillis, Teresa Helsten, Bella Kaufman, Yuan Yuan, Michael Friedlander, Meijing Wu, Cyril Ramathal, Véronique Diéras, Erin Murphy, Jean-Pierre M. Ayoub, Madan Gopal Kundu, Banu Arun, Christine K. Ratajczak, David Maag, Shannon Puhalla, Hans Wildiers, Vered Stearns
Publikováno v:
Clinical Cancer Research. 27:4983-4993
Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (gBRCA)-associated breast cancer enrolled in the BROCADE3 trial who received crossover vel
Autor:
Phyllis Dvora Corn, Dan Ariely, Ravi Varadhan, Anna Ferguson, B. Douglas Smith, Mirat Shah, Benjamin W. Corn, Vered Stearns, Thomas J. Smith
Publikováno v:
JCO Oncol Pract
PURPOSE: Hope is a modifiable entity that can be augmented. We evaluated the feasibility, acceptability, and efficacy of a short intervention to increase hopefulness in patients with advanced breast cancer and oncologists. METHODS: We enrolled eligib
Autor:
Amanda Vrselja, Ardian Latifi, Rodney J Baber, Bronwyn G A Stuckey, Michael G Walker, Vered Stearns, Martha Hickey, Susan R Davis
Publikováno v:
Lancet (London, England). 400(10364)
Vasomotor symptoms (hot flushes and night sweats) are experienced by more than two-thirds of women with breast cancer taking oral adjuvant endocrine therapy. Safe and effective treatments are lacking. Q-122 is a novel, non-hormonal compound that has
Autor:
Neha Verma, Amanda L. Blackford, Elissa Thorner, Jennifer Lehman, Claire Snyder, Vered Stearns, Karen Lisa Smith
Purpose:Sexual function problems are common but under-reported among women receiving adjuvant endocrine therapy for breast cancer. Worsening scores on patient-reported outcomes (PROs) may identify those at risk for sexual function problems during tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47ef4bda8af6f5a2efee3fc6ec3dc967
https://doi.org/10.21203/rs.3.rs-1685371/v1
https://doi.org/10.21203/rs.3.rs-1685371/v1
Autor:
Sheetal Parida, Sumit Siddharth, Nethaji Muniraj, Zhenhui Liu, Ishan Barman, Michael Smith, Jenni Sheng, Vered Stearns, Janelle W. Coughlin, Dipali Sharma
Publikováno v:
Cancer Research. 83:5916-5916
Background: 41.9% of adult US population is obese and every 5-unit BMI increase is associated with 12 percent increase in breast cancer risk; it is an independent predictor of poor outcomes in breast cancer. Microbiome has emerged as a central regula
Autor:
Aaron G. Baugh, Edgar Gonzalez, Valerie H. Narumi, Sofi Castanon, Jesse Kreger, James Leatherman, Won Jin Ho, Ashley Cimino-Mathews, Vered Stearns, Roisin M. Connolly, Elizabeth M. Jaffee, Adam L. MacLean, Evanthia T. Roussos Torres
Publikováno v:
Cancer Research. 83:5167-5167
Metastatic breast cancer remains one of the leading causes of global cancer incidence in women, despite the benefit of immune checkpoint inhibitors (ICIs) in managing various cancers and improving patient quality of life. Metastatic breast cancer is